Asset
NIVOLUMAB
Bristol-Myers Squibb Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $3.1B |
| Q1 2026 | $2.6B |
| Q4 2025 | $3.2B |
| Q3 2025 | $2.9B |
| Q2 2025 | $2.9B |
| Q1 2025 | $2.5B |
| Q4 2024 | $2.7B |
| Q3 2024 | $2.6B |
| Q2 2024 | $2.6B |
| Q1 2024 | $2.3B |
| Q4 2023 | $2.6B |
| Q3 2023 | $2.4B |
| Q2 2023 | $2.3B |
| Q1 2023 | $2.3B |
| Q4 2022 | $2.3B |
| Q3 2022 | $2.1B |
| Q2 2022 | $2.1B |
| Q1 2022 | $1.9B |
| Q4 2021 | $2.0B |
| Q3 2021 | $1.9B |
| Q2 2021 | $1.9B |
| Q1 2021 | $1.7B |
| Q4 2020 | $1.8B |
| Q3 2020 | $1.8B |
| Q2 2020 | $1.7B |
| Q1 2020 | $1.8B |
| Q4 2019 | $1.8B |
| Q3 2019 | $1.8B |
| Q2 2019 | $1.8B |
| Q1 2019 | $1.8B |
| Q4 2018 | $1.8B |
| Q3 2018 | $1.8B |
| Q2 2018 | $1.6B |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (213)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04151563 | phase1_2 | withdrawn | 2021-04-15 | 2023-12-17 | Bristol-Myers Squibb | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy |
| NCT03251924 | phase1_2 | terminated | 2017-09-01 | 2021-12-20 | Bristol-Myers Squibb | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors |
| NCT02713867 | phase3 | completed | 2016-05-24 | 2019-07-15 | Bristol-Myers Squibb | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks |
| NCT02998528 | phase3 | completed | 2017-03-04 | 2021-09-08 | Bristol-Myers Squibb | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) |
| NCT00730639 | phase1 | completed | 2008-10-30 | 2013-02-04 | Bristol-Myers Squibb | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies |
FDA applications (5)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| BLA 761381 | 2024-12-27 | BLA | Bristol-Myers Squibb Company |
| BLA 761234 | 2022-03-18 | BLA | Bristol-Myers Squibb Company |
| BLA 125554 | 2014-12-22 | BLA | Bristol-Myers Squibb Company |
| BLA 125527 | — | BLA | BRISTOL MYERS SQUIBB |
| BLA 761429 | — | BLA | BRISTOL-MYERS SQUIBB |
Marketed products (9)
- OPDIVO
- OPDIVO
- OPDIVO
- OPDIVO QVANTIG
- OPDIVO QVANTIG
- OPDUALAG
- Opdivo
- Opdivo
- Opdivo